We sought to characterise how AZD0424, and by extension SRC inhibitors in general, may be employed as part of anti‐cancer combination therapy in CRC as AZD0424 treatment could repress transducers of downstream signalling from EGFR, a key driver of metastatic CRC [25, 26]. Here, SRC is linked to colorectal carcinoma.